Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery

Mahasweta Paul; Raymond Lau

doi:10.1016/j.apt.2020.03.028

Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery

Mahasweta Paul, Raymond Lau^*

^*Corresponding author for this work

Nanyang Technological University

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Inhalation drug delivery has gained interests in delivery of Levodopa for the treatment of Parkinson's disease. In comparison to traditional oral delivery, delivery via intranasal or pulmonary pathways allows a slower drug degradation, greater drug bioavailability, increased blood plasma concentrations for longer periods and the ability to bypass the blood brain barrier. This review aims to highlight and summarize the recent advances made in the development of Levodopa particle formulations in terms of its characteristics, production techniques, choice of carrier materials, as well as pharmacokinetics and pharmacodynamics the formulations.

Original language	English
Pages (from-to)	2357-2365
Number of pages	9
Journal	Advanced Powder Technology
Volume	31
Issue number	6
DOIs	https://doi.org/10.1016/j.apt.2020.03.028
Publication status	Published - Jun 2020
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2020 The Society of Powder Technology Japan

ASJC Scopus Subject Areas

General Chemical Engineering
Mechanics of Materials

Keywords

Dry powder inhalation
Inhalation drug delivery
Particle characterization
Particle synthesis

Access to Document

10.1016/j.apt.2020.03.028

Cite this

@article{80b966e6b5f44c24ba48119493c68939,

title = "Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery",

abstract = "Inhalation drug delivery has gained interests in delivery of Levodopa for the treatment of Parkinson's disease. In comparison to traditional oral delivery, delivery via intranasal or pulmonary pathways allows a slower drug degradation, greater drug bioavailability, increased blood plasma concentrations for longer periods and the ability to bypass the blood brain barrier. This review aims to highlight and summarize the recent advances made in the development of Levodopa particle formulations in terms of its characteristics, production techniques, choice of carrier materials, as well as pharmacokinetics and pharmacodynamics the formulations.",

keywords = "Dry powder inhalation, Inhalation drug delivery, Particle characterization, Particle synthesis",

author = "Mahasweta Paul and Raymond Lau",

note = "Publisher Copyright: {\textcopyright} 2020 The Society of Powder Technology Japan",

year = "2020",

month = jun,

doi = "10.1016/j.apt.2020.03.028",

language = "English",

volume = "31",

pages = "2357--2365",

journal = "Advanced Powder Technology",

issn = "0921-8831",

publisher = "Elsevier BV",

number = "6",

}

TY - JOUR

T1 - Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery

AU - Paul, Mahasweta

AU - Lau, Raymond

PY - 2020/6

Y1 - 2020/6

N2 - Inhalation drug delivery has gained interests in delivery of Levodopa for the treatment of Parkinson's disease. In comparison to traditional oral delivery, delivery via intranasal or pulmonary pathways allows a slower drug degradation, greater drug bioavailability, increased blood plasma concentrations for longer periods and the ability to bypass the blood brain barrier. This review aims to highlight and summarize the recent advances made in the development of Levodopa particle formulations in terms of its characteristics, production techniques, choice of carrier materials, as well as pharmacokinetics and pharmacodynamics the formulations.

AB - Inhalation drug delivery has gained interests in delivery of Levodopa for the treatment of Parkinson's disease. In comparison to traditional oral delivery, delivery via intranasal or pulmonary pathways allows a slower drug degradation, greater drug bioavailability, increased blood plasma concentrations for longer periods and the ability to bypass the blood brain barrier. This review aims to highlight and summarize the recent advances made in the development of Levodopa particle formulations in terms of its characteristics, production techniques, choice of carrier materials, as well as pharmacokinetics and pharmacodynamics the formulations.

KW - Dry powder inhalation

KW - Inhalation drug delivery

KW - Particle characterization

KW - Particle synthesis

UR - http://www.scopus.com/inward/record.url?scp=85083305054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083305054&partnerID=8YFLogxK

U2 - 10.1016/j.apt.2020.03.028

DO - 10.1016/j.apt.2020.03.028

M3 - Article

AN - SCOPUS:85083305054

SN - 0921-8831

VL - 31

SP - 2357

EP - 2365

JO - Advanced Powder Technology

JF - Advanced Powder Technology

IS - 6

ER -

Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Keywords

Access to Document

Other files and links

Fingerprint

Cite this